Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: The effect of α-tocopherol supplementation

Circulation

Volumn 102, Issue 2, 2000, Pages 191-196

  Devaraj, S ^a   Jialal, I ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cell adhesion molecules; Cells; Diabetes; Proteins; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETIC ANGIOPATHY; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SECRETION; VITAMIN SUPPLEMENTATION;

EID: 0034636751     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.2.191     Document Type: Article

References (50)

1. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes. 1987;3:463-524.
2. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12: 647-656.
3. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol. 1993;71:26B-31B.
4. Brownlee M. Advanced glycation endproducts in diabetic complications. Curr Opin Endocrinol Diabetes. 1996;3:291-297.
5. Witztum JL, Steinberg D. Role of ox-LDL in atherogenesis. J Clin Invest. 1991;88:1785-1792.
6. Devaraj S, Jialal I. Oxidized LDL and atherosclerosis. Int J Clin Lab Res. 1996;26:178-184.
7. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications. Curr Opin Endocrinol. 1996;3:277-284.
8. Oranje WA, Wolffenbuttel BHR. Lipid peroxidation and atherosclerosis in type 2 diabetes. J Lab Clin Med. 1999;134:19-32.
9. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347:444-445.
10. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arterioscler Thromb Vasc Biol. 1995;15:190-198.
11. Kitahara M, Eyre H, Lynch RE, et al. Metabolic activity of diabetic monocytes Diabetes. 1980;29:251-256.
12. Hiramatsu K, Rosen H, Heinecke J, et al. Superoxide initiates oxidation of LDL by human monocytes. Arteriosclerosis. 1987;7:55-60.
13. Kim HA, Berliner JA, Natarajan RD, et al. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes. 1994;43:1103-1107.
14. Carantoni M, Abbasi F, Chu L, et al. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM. Diabetes Care. 1997;20:1462-1466.
15. Hoogerbrugge N, Verkerk A, Jacobs ML, et al. Hypertriglyceridemia enhances monocyte binding to endothelial cells in NIDDM. Diabetes Care. 1997;3:1122-1124.
16. Devaraj S, Li D, Jialal I. The effect of AT on monocyte function: decreased lipid oxidation, IL-1β secretion and adhesion to endothelium. J Clin Invest. 1996;98:756-763.
17. Islam KN, Devaraj S, Jialal I. α-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to endothelial cells. Circulation. 1998;98:2255-2261.
18. Devaraj S, Jialal I. α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol. 1999;19:1125-1133.
19. Hwang S, Ballantyne CM, Sharrett AR. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary artery disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:4219-4225.
20. De Mattia G, Bravi MC, Laurenti O, et al. Reduction of oxidative stress by oral NAC treatment decreases sVCAM-1 concentrations in non-obese, normotensive patients with NIDDM. Diabetologia. 1998;41:1392-1396.
21. Li D, Devaraj S, Fuller CJ, et al. Effect of AT on LDL oxidation: in vivo and in vitro studies. J Lipid Res. 1996;37:1978-1996.
22. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from CHD in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
23. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
24. Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) trial. Lancet. 1998;351:1755-1762.
25. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with CAD: a subgroup analysis of 4S. Diabetes Care. 1997;20:614-620.
26. Goldberg R, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998; 98:2513-2519.
27. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
28. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with CHD and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
29. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of AT in patients with coronary disease: CHAOS. Lancet. 1996;347: 781-786.
30. Steiner M, Glantz M, Lekos A. AT plus aspirin compared with aspirin alone in patients with TIA. Am J Clin Nutr. 1995;62:1381S-1384S.
31. Jialal I, Devaraj S, Huet BA, et al. GISSI-Prevenzione Trial. Lancet. 1999;354:1554.
32. Yegin A, Ozben T. Serum glycated lipoproteins in type 2 diabetic patients with and without complications. Ann Clin Biochem. 1995;32:459-463.
33. Kobayashi K, Ogasahara N, Sakoguchi T, et al. Agarose gel electrophoresis with NBT for determination of glycated lipoproteins in serum from diabetics. Clin Chem. 1990;36:65-69.
34. Ceriello A, Giugliano D, Quatraro A. et al. AT reduction of protein glycosylation in diabetics: new prospect for prevention of diabetic complications. Diabetes Care. 1991;14:68-72.
35. Paolisso G, D'Amore A, Galzerano D, et al. Daily AT supplementation improves control but not insulin secretion in elderly type 2 diabetic patients. Diabetes Care. 1993;16:433-437.
36. Jain SK, McVie R, Jaramillo JJ, et al. Effect of modest AT supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type 1 diabetic patients. J Am Coll Nutr. 1996;15:458-461.
37. Reaven PD, Herold DA, Barnett J, et al. Effects of AT on susceptibility of LDL and LDL subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 1995;18:807-816.
38. Fuller CJ, Chandalia M, Garg A, et al. RRR-AT supplementation at pharmacological doses decreases LDL oxidative susceptibility but not protein glycation in patients with DM. Am J Clin Nutr. 1996;63: 753-759.
39. Mol MJTM, de Rijke YB, Demacker PNM, et al. Plasma levels of lipid and cholesterol oxidation products and cytokines in DM and cigarette smoking: effects of AT treatment. Atherosclerosis. 1997;129:169-176.
40. Leinonen JS, Rantalaiho V, Solakivi T, et al. Susceptibility of LDL to oxidation is not associated with the presence of coronary artery disease or renal dysfunction in NIDDM patients. Clin Chim Acta. 1998;275: 163-174.
41. Hill HR, Hogan NA, Rallison ML, et al. Functional and metabolic abnormalities of diabetic monocytes. Adv Exp Med Biol. 1980;69: 621-627.
42. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Circulation. 1998;98:2255-2261.
43. Desfaits A, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion and TNF production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998;21:487-491.
44. Cominacini L, Fratta Pasini A, Garbin U. Elevated levels of sE-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia. 1995;38:1122-1124.
45. Steiner M, Reinhardt KM, Krammer B, et al. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Hemost. 1994;72: 979-984.
46. Albertini J, Valensi P, Lormeau B, et al. Elevated concentrations of sE-selectin and VCAM-1 in NIDDM. Diabetes Care. 1998;21: 1008-1013.
47. Cominacini L, Garbin U, Pasini AF, et al. Troglitazone reduces LDL oxidation and lowers sE-selectin in NIDDM. Diabetes. 1998;47: 130-133.
48. Bursell SE, Clermont AC, Aiello LP, et al. High dose AT supplementation normalizes retinal blood flow and creatinine clearance in patients with type I diabetes. Diabetes Care. 1999;22:1245-1251.
49. Gisinger C, Jeremy J, Spieser P, et al. Effect of AT supplementation on platelet thromboxane A2 production in type I diabetic patients. Diabetes. 1988;37:1260-1264.
50. Jain SK, Krueger KS, McVie R, et al. Relationship of TxB2 with LPO and effect of vitamin E on these levels in type 1 diabetic patients. Diabetes Care. 1998;21:1511-1516.